Inhibition of Cdk2 kinase activity selectively targets the CD44 +/CD24-/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells

International Journal of Oncology

Volumn 45, Issue 3, 2014, Pages 1193-1199

  Opyrchal, Mateusz ^a   Salisbury, Jeffrey L ^b   Iankov, Ianko ^a   Goetz, Mathew P ^a   McCubrey, James ^c   Gambino, Mario W ^b   Malatino, Lorenzo ^d   Puccia, Giuseppe ^d   Ingle, James N ^a   Galanis, Evanthia ^a   D'Assoro, Antonino B ^a,b  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c EAST CAROLINA UNIVERSITY   (United States)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

Breast cancer; Cancer stem cells; Cell cycle; Centrosome amplification; Chromosomal instability; Cyclin E; Metastases

Indexed keywords

ANTINEOPLASTIC AGENT; CD24 ANTIGEN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN E; HERMES ANTIGEN; METHOTREXATE; PACLITAXEL; SU 9516; UNCLASSIFIED DRUG; CDK2 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER CELL LINE; CANCER CELL; CANCER CHEMOTHERAPY; CELL EXPANSION; CELL SUBPOPULATION; CENTROSOME; CHEMOSENSITIVITY; CHROMOSOME ABERRATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MCF 7 CELL LINE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETINOBLASTOMA; TRIPLE NEGATIVE BREAST CANCER; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CANCER STEM CELL; CHROMOSOMAL INSTABILITY; DRUG EFFECTS; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; INFLAMMATORY BREAST NEOPLASMS; METABOLISM; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANTIGENS, CD24; ANTIGENS, CD44; APOPTOSIS; CELL LINE, TUMOR; CHROMOSOMAL INSTABILITY; CYCLIN-DEPENDENT KINASE 2; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; IMIDAZOLES; INDOLES; INFLAMMATORY BREAST NEOPLASMS; MCF-7 CELLS; NEOPLASTIC STEM CELLS; PACLITAXEL; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84904392767     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2523     Document Type: Article

References (40)

1. Fernandez SV, Robertson FM, Pei J, Aburto-Chumpitaz L, Mu Z, Chu K, Alpaugh RK, Huang Y, Cao Y, Ye Z, Cai KQ, Boley KM, Klein-Szanto AJ, Devarajan K, Addya S and Cristofanilli M: Inflammatory breast cancer (IBC): clues for targeted therapies. Breast Cancer Res Treat 140: 23-33, 2013.
2. Yasumura K, Ogawa K, Ishikawa H, Takeshita T, Nakagawa Y and Osamura RY: Inflammatory carcinoma of the breast: characteristic findings of MR imaging. Breast Cancer 4: 161-169, 1997.
3. Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, Iwamoto T, Krishnamurthy S, Yang W, Reuben JM, Hortobágyi GN and Ueno NT: Inflammatory breast cancer: what we know and what we need to learn. Oncologist 17: 891-899, 2012.
4. Liedtke C, Bernemann C, Kiesel L and Rody A: Genomic profiling in triple-negative breast cancer. Breast Care (Basel) 8: 408-413, 2013.
5. Qiu M, Peng Q, Jiang I, Carroll C, Han G, Rymer I, Lippincott J, Zachwieja J, Gajiwala K, Kraynov E, Thibault S, Stone D, Gao Y, Sofia S, Gallo J, Li G, Yang J, Li K and Wei P: Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells. Cancer Lett 328: 261-270, 2013.
6. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W and von Minckwitz G: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet: Feb 14, 2014 (Epub ahead of print).
7. Crown J, O'Shaughnessy J and Gullo G: Emerging targeted therapies in triple-negative breast cancer. Ann Oncol 23 (Suppl 6): vi56-vi65, 2012.
8. Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, King R, McLennan J, Crawford B, Kelly Marcom P and Shelley Hwang E: Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol 20: 3254-3258, 2013.
9. Venkitaraman AR: Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108: 171-182, 2002.
10. Farrugia DJ, Agarwal MK, Pankratz VS, Deffenbaugh AM, Pruss D, Frye C, Wadum L, Johnson K, Mentlick J, Tavtigian SV, Goldgar DE and Couch FJ: Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res 68: 3523-3531, 2008.
11. Kais Z, Chiba N, Ishioka C and Parvin JD: Functional differences among BRCA1 missense mutations in the control of centrosome duplication. Oncogene 31: 799-804, 2012.
12. Kolupaeva V and Basilico C: Overexpression of cyclin E/CDK2 complexes overcomes FGF-induced cell cycle arrest in the presence of hypophosphorylated Rb proteins. Cell Cycle 11: 2557-2566, 2012.
13. Reed SI: Control of the G1/S transition. Cancer Surv 29: 7-23, 1997.
14. D'Assoro AB, Lingle WL and Salisbury JL: Centrosome amplification and the development of cancer. Oncogene 21: 6146-6153, 2002.
15. D'Assoro AB, Busby R, Suino K, Delva E, Almodovar-Mercado GJ, Johnson H, Folk C, Farrugia DJ, Vasile V, Stivala F and Salisbury JL: Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint. Oncogene 23: 4068-4075, 2004. (Pubitemid 38747937)
16. Hanashiro K, Kanai M, Geng Y, Sicinski P and Fukasawa K: Roles of cyclins A and E in induction of centrosome amplification in p53-compromised cells. Oncogene 27: 5288-5302, 2008.
17. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J and Weinberg RA: The epithelial mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715, 2008. (Pubitemid 351636299)
18. Hwang-Verslues WW, Kuo WH, Chang PH, Pan CC, Wang HH, Tsai ST, Jeng YM, Shew JY, Kung JT, Chen CH, Lee EY, Chang KJ and Lee WH: Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One 4: 8377, 2009.
19. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS and Polyak K: Molecular definition of breast tumor heterogeneity. Cancer Cell 11: 259-273, 2007. (Pubitemid 46349843)
20. D'Assoro AB, Liu T, Quatraro C, Amato A, Opyrchal M, Leontovich A, Ikeda Y, Ohmine S, Lingle W, Suman V, Ecsedy J, Iankov I, Di Leonardo A, Ayers-Inglers J, Degnim A, Billadeau D, McCubrey J, Ingle J, Salisbury JL and Galanis E: The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells. Oncogene 33: 599-610, 2014.
21. Lee HE, Kim JH, Kim YJ, Choi SY, Kim SW, Kang E, Chung IY, Kim IA, Kim EJ, Choi Y, Ryu HS and Park SY: An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer 104: 1730-1738, 2011.
22. Arima Y, Hayashi N, Hayashi H, Sasaki M, Kai K, Sugihara E, Abe E, Yoshida A, Mikami S, Nakamura S and Saya H: Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer. Int J Cancer 130: 2568-2579, 2012.
23. Prat A, Karginova O, Parker JS, Fan C, He X, Bixby L, Harrell JC, Roman E, Adamo B, Troester M and Perou CM: Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res Treat 142: 237-255, 2013.
24. D'Assoro AB, Leontovich A, Amato A, Ayers-Ringler JR, Quatraro C, Hafner K, Jenkins RB, Libra M, Ingle J, Stivala F, Galanis E and Salisbury JL: Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts. Int J Oncol 37: 1167-1176, 2010.
25. D'Assoro AB, Barrett SL, Folk C, Negron VC, Boeneman K, Busby R, Whitehead C, Stivala F, Lingle WL and Salisbury JL: Amplified centrosomes in breast cancer: a potential indicator of tumor aggressiveness. Breast Cancer Res Treat 75: 25-34, 2002.
26. Iovino F, Lentini L, Amato A and Di Leonardo A: RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts. Mol Cancer 5: 38, 2006.
27. Mayer IA, Abramson VG, Lehmann BD and Pietenpol JA: New strategies for triple-negative breast cancer - deciphering the heterogeneity. Clin Cancer Res 20: 782-790, 2014.
28. Mehta RS: Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox. J Clin Oncol 26: 3286-3288, 2008.
29. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN and Pusztai L: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26: 1275-1281, 2008.
30. Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C and Hortobagyi GN: Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 92: 1775-1782, 2001. (Pubitemid 32952495)
31. Takahashi T, Akashi-Tanaka S, Fukutomi T, Watanabe T, Katsumata N, Miyakawa K, Hasegawa T and Tsuda H: Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin. Breast Cancer 8: 234-237, 2001.
32. Leopold PL, Vincent J and Wang H: A comparison of epithelialto- mesenchymal transition and re-epithelialization. Semin Cancer Biol 22: 471-483, 2012.
33. Rosen EM, Pishvaian MJ: Targeting the BRCA1/2 tumor suppressors. Curr Drug Targets 15: 17-31, 2014.
34. Khoury-Haddad H, Guttmann-Raviv N, Ipenberg I, Huggins D, Jeyasekharan AD and Ayoub N: PARP1-dependent recruitment of KDM4D histone demethylase to DNA damage sites promotes double-strand break repair. Proc Natl Acad Sci USA 111: E728-E737, 2014.
35. Wȩsierska-Ga̧dek J, Zulehner N, Ferk F, Składanowski A, Komina O and Maurer M: PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells. Biochem Pharmacol 84: 1318-1331, 2012.
36. Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE and Ashworth A: BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res 19: 5003-5015, 2013.
37. Fojo T and Bates S: Mechanisms of resistance to PARP inhibitors - three and counting. Cancer Discov 3: 20-23, 2013.
38. Yin S, Xu L, Bandyopadhyay S, Sethi S and Reddy KB: Cisplatin and TRAIL enhance breast cancer stem cell death. Int J Oncol 39: 891-898, 2011.
39. Potemski P, Kusińska R, Pasz-Walczak G, Piekarski JH, Watała C, Płuciennik E, Bednarek AK and Kordek R: Prognostic relevance of cyclin E expression in operable breast cancer. Med Sci Monit 15: MT34-MT40, 2009.
40. Willmarth NE, Albertson DG and Ethier SP: Chromosomal instability and lack of cyclin E regulation in hCdc4 mutant human breast cancer cells. Breast Cancer Res 6: R531-R539, 2004.